Vaccine Info

LC16 KMB (LC16m8) Monkeypox (Smallpox) Vaccine

Authored by
Last reviewed
September 20, 2022
Fact checked by
Robert Carlson, MD

LC16 KMB (LC16m8) Monkeypox Vaccine

Japan-based KM Biologics LC16 KMB (LC16m8) is formulated as a freeze-dried cell culture smallpox and monkeypox vaccine. LC16 is a 3rd generation, live attenuated vaccine containing live vaccinia virus (LC16m8 strain) used to prevent smallpox (market authorized for all ages in 1975 in Japan / licensed under the emergency investigational new drug program in the U.S. The LC16m8 was an attenuated cell culture–adapted Lister vaccinia smallpox vaccine missing the B5R protein

In contrast to replication-deficient vaccines such as Modified Vaccinia Ankara, LC16m8 retains most of the vaccinia genome. Therefore, it can replicate at the inoculation site, producing a "take lesion" in vaccinees.

On August 2, 2022, Japan's Ministry of Health, Labour, and Welfare (MHLW) announced the approval of this smallpox vaccine for voluntary vaccinations as pre-exposure prophylaxis (PrEP) against the monkeypox virus. This approval followed an advisory committee review. On August 3, 2022, Meiji Holdings announced 'Notification of Additional Approval of Indication for "Monkeypox Prevention for Freeze-dried Cell Culture Smallpox Vaccine LC16 KMB." On August 31, 2022, Indonesia's National Agency of Drug and Food Control is reviewing authorization.

In 2017, a study concluded that 'Inoculation of LC16m8 into humans induced neutralizing antibodies against smallpox virus, and the effect was similar to that of the ACAM2000 smallpox vaccine. The results were presented at the 19th ACVVR Congress (WHO) in 2017.' Since 1976, the Japanese government has discontinued the national vaccination program for smallpox. Japan's government authorized the LC16 KMB vaccine's indication for monkeypox on August 2, 2022.

KM Biologics (SVRG Kaketsuken) is a unit of Japanese food and pharmaceuticals company Meiji Holdings, based in Kumamoto, 860-8568, Japan. Click here for the Meiji Group 2026 Vision.

LC16 KMB Monkeypox Vaccine Indication

LC16 KBM vaccine has been approved in Japan for smallpox and monkeypox pre-exposure prophylaxis (PrEP).

LC16 KBM Vaccine Storage

The long-term storage stability of LC16m8 (formulation: 10 years, drug substance: 5 years) confirmed the high storage stability of LC16m8. 

LC16 KBM Vaccine Dosage

LC16m8 is administered as a single dose using the traditional scarification method.

Japan Smallpox Vaccine

The Japanese government decided that all residents should be immunized with a smallpox vaccine in 1876, and a vaccination law against smallpox started in 1910. In the twenty years from 1889 to 1908, 171,500 cases of smallpox, and in 1908 there were 18,139 cases. The present immunization law was implemented in 1948 under occupation by the USA. In 2002, a study was published on Japan's smallpox vaccination program.

LC16 KMB Vaccine News

September 15, 2022 - The Lancet published: Prevention of monkeypox with vaccines: a rapid review.

August 31, 2022 - Director of Bio Farma Honesti Basyir said Indonesia's government is targeting three monkeypox vaccines, including LC16M8 (SVRG Kaketsuken Japan).

August 5, 2022 - Australian media reported: The only other non-replicating vaccine is the LC16m8 from Japan, and scaling up production is difficult, so supplies are limited.

August 2, 2022 - Japan's MHLW presented Plan for Monkeypox Vaccinations with KM Biologics' smallpox vaccine.

August 2, 2022 - WHO Monkeypox Research - What study designs can be used to address the remaining knowledge gaps for monkeypox vaccines?

June 14, 2022 - The Ministry of Health, Labour, and Welfare published a press release: Vaccines and immunization for monkeypox: Interim guidance.

February 3, 2021 - PLOS Pathogens published a RESEARCH ARTICLE: A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndrome.

April 28, 2015 - ASM Journals published: Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky.

March 11, 2009 - The JAMA Network published: Clinical and Immunological Response to Attenuated Tissue-Cultured Smallpox Vaccine LC16m8. Conclusion Administration of an attenuated tissue-cultured smallpox vaccine (LC16m8) to healthy adults was associated with high levels of vaccine take and seroconversion in those vaccinia-naive and yielded an effective booster response in some previously vaccinated individuals.

LC16 KMB Clinical Trials

A single-arm clinical study to evaluate the immunogenicity and safety of smallpox vaccine as vaccination to monkeypox in healthy Japanese adults (MKP-3 study). The outline of this study and results have been published in the Clinical Research Implementation Plan and Research Outline Disclosure System (jRCT). In addition, Japan's health ministry vaccinated 50 medical workers at the National Center for Global Health and Medicine for research purposes in July 2022.

2017 - Research on the efficacy, safety, and productivity improvement of cell-cultured smallpox vaccines developed and stockpiled in Japan and on the ideal countermeasures against bioterrorism in Japan and overseas. We analyzed the ability of LC16m8 to induce neutralizing antibodies against the smallpox virus through joint research by the US CDC and this research group. Stability results of LC16m8 during long-term cryopreservation were obtained. In addition, a study on the post-exposure inoculation effect of LC16m8 was carried out.

Clinical Trials

No clinical trials found